Observational studyESC heart failure2024
Setting the optimal threshold of NT-proBNP and BNP for the diagnosis of heart failure in patients over 75 years.
Observational study in ESC heart failure, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Economic evaluation of NT-proBNP testing plus standard clinical assessment versus standard clinical assessment alone for the prevention of heart failure in older adults with type 2 diabetes.BMJ open diabetes research & care · 2026Article
- Artificial intelligence-powered electrocardiogram is superior to NT-proBNP in predicting left ventricular systolic dysfunction in atrial fibrillation with rapid ventricular response.Heart rhythm O2 · 2026Article
- Clinical characteristics and serum HDL-C are associated with adverse prognosis in patients with acute decompensated heart failure with preserved ejection fraction at admission.Frontiers in cardiovascular medicine · 2026Article
- Lung Ultrasound Offers Fast and Reliable Exclusion of Heart Failure in the Emergency Department: A Prospective Diagnostic Study.Diagnostics (Basel, Switzerland) · 2025Article
- Heart failure and chronic obstructive pulmonary disease. A combination not to be underestimated.Heart failure reviews · 2025Review
- Cardiomyopathy in Older Adults.Current cardiology reports · 2025Review
- Combining clinical markers can predict mortality in NYHA IV heart failure.Scientific reports · 2025Article
- Identification of hub genes for the diagnosis associated with heart failure using multiple cell death patterns.ESC heart failure · 2025Article
- Heart Failure in Older Patients: An Update.Journal of clinical medicine · 2025Review
- Predictive value of baseline serum sST2 and BNP levels for treatment efficacy in patients with heart failure.American journal of translational research · 2025Article
- Refining the diagnosis of acute heart failure in the elderly.ESC heart failure · 2024Article
- Current Review of Heart Failure-Related Risk and Prognostic Factors.Biomedicines · 2024Review
- Setting the optimal threshold of NT-proBNP and BNP for the diagnosis of heart failure in patients over 75 years.ESC heart failure · 2024Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsDiagnosing acute heart failure (AHF) remains particularly challenging in older patients. Natriuretic peptides are recommended as valuable diagnostic tools in this context. This study aims to establish the diagnostic thresholds of B-type natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) for AHF in patients aged over 75 years, both with and without co-morbidities. METHODS AND
resultsIn this retrospective longitudinal multicentre cohort study, data were gathered from 12 071 hospitalized patients aged 75 years or older, presenting with acute dyspnoea and undergoing BNP or NT-proBNP measurement within 48 h of admission across 10 Assistance Publique-Hôpitaux de Paris facilities between 2011 and 2022, encompassing geriatrics, cardiology, and pulmonology departments. Final diagnoses were categorized using ICD-10 criteria as either AHF or other acute respiratory conditions such as COPD exacerbation, pulmonary embolism, and pneumonia. The mean (SD) age of the population was 84.0 (80.0, 89.0) years, with 52.7% being female. Out of these, 7946 (65.8%) were diagnosed with AHF upon discharge. For NT-proBNP, the identified 'optimal' threshold for diagnosing AHF was 1748 ng/L, with a positive predictive value (PPV) of 84%. Among patients aged over 85 years, a threshold of 2235 pg/mL for NT-proBNP was associated with an 84% PPV. In patients with atrial fibrillation (AF), a threshold of 2332 pg/mL for NT-proBNP demonstrated a PPV of 90% for AHF diagnosis. Additionally, in patients with an estimated glomerular filtration rate (eGFR) < 30 mL/min, a threshold of 3474 pg/mL for NT-proBNP yielded a 90% PPV for AHF diagnosis. In male patients, a threshold of 1800 pg/mL showed an 85% PPV for AHF diagnosis, while in patients with obesity, a threshold of 1375 pg/mL demonstrated an 85% PPV for AHF diagnosis.
conclusionsIn older patients, we found significant effects of co-morbidities on natriuretic peptides results, particularly in patients over 85 years old, older patients with abnormal renal function, obesity, and atrial fibrillation. Despite the consideration of those co-morbid conditions, NT-proBNP and BNP level continue to demonstrate utility in the diagnosis of AHF in older patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.